{
    "id": "6422e7ba690f196b51000044",
    "question": "Have Quercetin-biapigenin nanoparticles been shown to be effective in penetrating the blood-brain barrier",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "A",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, we need to consider the properties of quercetin-biapigenin nanoparticles and their interaction with the blood-brain barrier. The blood-brain barrier is a highly selective permeable barrier that restricts the passage of certain substances from the bloodstream to the brain tissue. The size of the nanoparticles can play a crucial role in their ability to penetrate the blood-brain barrier. According to document [18], nanoparticles with a size between 1 and 100 nanometers can be used to deliver drugs across the blood-brain barrier. Quercetin-biapigenin nanoparticles have a size in this range, so they may be able to penetrate the blood-brain barrier. However, the effectiveness of these nanoparticles in penetrating the blood-brain barrier is not explicitly stated in the provided documents. We need to look for any information that may indicate their ability to cross the blood-brain barrier. Document [18] states that nanoparticles can be used to deliver drugs across the blood-brain barrier, but it does not specifically mention quercetin-biapigenin nanoparticles. Document [20] mentions that large molecules, such as albumin, are prevented from entry by the capillary endothelium, but it does not provide information on the ability of quercetin-biapigenin nanoparticles to cross the blood-brain barrier. Document [22] discusses the permeation of drugs across the blood-brain barrier, but it does not mention nanoparticles. Based on the available information, we cannot conclude that quercetin-biapigenin nanoparticles have been shown to be effective in penetrating the blood-brain barrier. Therefore, the answer is not explicitly stated in the provided documents. However, considering the size of the nanoparticles and the general information about the blood-brain barrier, we can infer that quercetin-biapigenin nanoparticles may have the potential to penetrate the blood-brain barrier. The best answer is not explicitly stated in the provided documents, but based on the information available, the most likely answer is B. no, but with the understanding that the actual answer could be A. yes if more specific information is available.\", \"answer_choice\": \"B\"}",
    "snippets": [
        {
            "id": "Histology_Ross_1889",
            "title": "Histology_Ross",
            "content": "The blood\u2013brain barrier restricts passage of certain ions and substances from the bloodstream to tissues of the CNS. The presence of only a few small vesicles indicates that pinocytosis across the brain endothelial cells is severely restricted. Substances with a molecular weight greater than 500 daltons generally cannot cross the blood\u2013brain barrier. Many molecules that are required for neuronal integrity leave and enter the blood capillaries through the endothelial cells. Thus, O2 and CO2 as well as certain lipid-soluble molecules (e.g., ethanol and steroid hormones) easily penetrate the endothelial cells and pass freely between the blood and extracellular fluid of the CNS. Due to the high K permeability of the neuronal membrane, neurons are particularly sensitive to changes in the concentration of extracellular K. As previously discussed, astrocytes are foot processes of astrocytes FIGURE 12.32 \u2022 Schematic drawing of blood\u2013brain barrier."
        },
        {
            "id": "Pharmacology_Katzung_6354",
            "title": "Pharmacology_Katzung",
            "content": "Human toxicology\u2014Inhalation, oral ingestion, dermal absorption, and parenteral administration of nanomaterials have been the sources of human exposure. Because of the unique physicochemical properties of nanomaterials, their toxicity may be similar to or very different from the larger, bulk materials encountered in traditional toxicology studies. The nature of the exposure will impact the likelihood that nanomaterials will reach target organs or cells. Nanomaterials can cross cellular membranes, penetrate nuclear material and genetic information, and may impact cellular response at a nanoscale. Silica nanoparticles have been demonstrated to produce kidney toxicity in humans, and zinc oxide nanoparticles are toxic to human liver cells. Multiwalled carbon nanotubes have been found to be cytotoxic in human lung cells. Titanium dioxide nanoparticles that are widely used in sunscreens, other cosmetics, pharmaceuticals, and many other products have been noted to be toxic in the lungs and"
        },
        {
            "id": "Pharmacology_Katzung_2182",
            "title": "Pharmacology_Katzung",
            "content": "The blood-brain barrier (BBB) is a protective functional separation of the circulating blood from the extracellular fluid of the CNS that limits the penetration of substances, including drugs. This separation is accomplished by the presence of tight junctions between the capillary endothelial cells as well as a surrounding layer of astrocyte end-feet. As such, to enter the CNS, drugs must either be highly hydrophobic or engage specific transport mechanisms. For example, the second-generation antihistamines cause less drowsiness because they were developed to be significantly more polar than older antihistamines, limiting their crossing of the BBB (see Chapter 16). Many nutrients, such as glucose and the essential amino acids, have specific transporters that allow them to cross the BBB. l-DOPA, a precursor of the neurotransmitter dopamine, can enter the brain using an amino acid transporter, whereas dopamine cannot cross the BBB. Thus, the orally administered drug l-DOPA, but not"
        },
        {
            "id": "Histology_Ross_1886",
            "title": "Histology_Ross",
            "content": "The blood\u2013brain barrier protects the CNS from fluctuating levels of electrolytes, hormones, and tissue metabolites circulating in the blood vessels. The observation more than 100 years ago that vital dyes injected into the bloodstream can penetrate and stain nearly all organs except the brain provided the first description of the blood\u2013brain barrier. More recently, advances in microscopy and molecular biology techniques have revealed the precise location of this unique barrier and the role of endothelial cells in transporting essential substances to the brain tissue."
        },
        {
            "id": "Neurology_Adams_9494",
            "title": "Neurology_Adams",
            "content": "To enter the extracellular compartment of the nervous system, a drug or toxic agent must transgress the tight capillary\u2013endothelial barrier (blood\u2013brain barrier) and the barrier between the blood and cerebrospinal fluid (blood\u2013CSF barrier). Intrathecal injection circumvents these barriers, but then the agent tends to concentrate in the immediate subpial and subependymal regions. The process of movement from plasma to brain is by diffusion through capillaries or by facilitated transport. The solubility characteristics of the drug determine its rate of diffusion."
        },
        {
            "id": "Histology_Ross_1888",
            "title": "Histology_Ross",
            "content": "Evidence suggests that the integrity of blood\u2013brain barrier tight junctions depends on normal functioning of the associated astrocytes. In several brain diseases, the blood\u2013brain barrier loses effectiveness. Examination of brain tissue in these conditions by TEM reveals loss of the tight junctions as well as alterations in the morphology of astrocytes. Other experimental evidence has revealed that astrocytes release soluble factors that increase barrier properties and tight junction protein content."
        },
        {
            "id": "Pediatrics_Nelson_3327",
            "title": "Pediatrics_Nelson",
            "content": "The blood-brain barrier prevents the penetration of chemotherapeutic drugs into the CNS; instillation of the chemotherapeutic agent directly into the cerebrospinal fluid (by lumbar puncture) may be necessary. Radiation therapy also circumvents the blood-brain barrier. Radiation therapy is the process of delivering ionizing radiationto malignant cells in order to kill them directly or, more commonly, prevent them from dividing by interfering with DNAreplication. Conventional radiation therapy uses photons, butatomic particles such as electrons, protons, and neutrons canalso be used. Not all tumors are radiosensitive, and radiation therapy is not necessary in all tumors that are radiosensitive."
        },
        {
            "id": "Histology_Ross_1890",
            "title": "Histology_Ross",
            "content": "FIGURE 12.32 \u2022 Schematic drawing of blood\u2013brain barrier. This drawing shows the blood\u2013brain barrier, which consists of endothelial cells joined together by elaborate, complex tight junctions, endothelial basal lamina, and the end foot processes of astrocytes. responsible for buffering the concentration of K in the brain extracellular fluid (page 369). They are assisted by endothelial cells of the blood\u2013brain barrier that effectively limit movement of K into the extracellular fluid of the CNS. Substances that do cross the capillary wall are actively transported by specific receptor-mediated endocytosis. For instance, glucose (which the neuron depends on almost exclusively for energy), amino acids, nucleosides, and vitamins are actively transported by specific transmembrane carrier proteins. The permeability of the blood\u2013brain barrier to these macromolecules is attributable to the level of expression of specific carrier proteins on the endothelial cell surface."
        },
        {
            "id": "Histology_Ross_1891",
            "title": "Histology_Ross",
            "content": "Several other proteins that reside within the plasma membrane of endothelial cells protect the brain by metabolizing certain molecules, such as drugs and foreign proteins, thus preventing them from crossing the barrier. For example, L-dopa (levodopa), the precursor of the neuromediators dopamine and noradrenaline, easily crosses the blood\u2013brain barrier. However, the dopamine formed from the decarboxylation of L-dopa in endothelial cells cannot cross the barrier and is restricted from the CNS. In this case, the blood\u2013brain barrier regulates the concentration of L-dopa in the brain. Clinically, this restriction explains why L-dopa is administered for the treatment of dopamine deficiency (e.g., Parkinson\u2019s disease) rather than dopamine."
        },
        {
            "id": "InternalMed_Harrison_347",
            "title": "InternalMed_Harrison",
            "content": "Drug movement across the membrane of any cell, including enterocytes and hepatocytes, is a combination of passive diffusion and active transport, mediated by specific drug uptake and efflux molecules. One widely studied drug transport molecule is P-glycoprotein, the product of the MDR1 gene. P-glycoprotein is expressed on the apical aspect of the enterocyte and on the canalicular aspect of the hepatocyte (Fig. 5-3). In both locations, it serves as an efflux pump, limiting availability of drug to the systemic circulation. P-glycoprotein\u2013mediated drug efflux from cerebral capillaries limits drug brain penetration and is an important component of the blood-brain barrier."
        },
        {
            "id": "Physiology_Levy_324",
            "title": "Physiology_Levy",
            "content": "Nervous Tissue Reactions to Injury Injury to nervous tissue elicits responses by neurons and glia. Severe injury causes cell death. Except in specific instances, once a neuron is lost it cannot be replaced because, in general, CHAPTER 4 The Nervous System: Introduction to Cells and Systems 63 The blood-brain barrier can be disrupted by pathology of the brain. For example, brain tumors may allow substances that are otherwise excluded to enter the brain from the circulation. Radiologists can exploit this by introducing a substance into the circulation that normally cannot penetrate the blood-brain barrier. If the substance can be imaged, its leakage into the region occupied by the brain tumor can be used to demonstrate the distribution of the tumor. neurons are postmitotic cells. In animals, two exceptions are olfactory bulb and hippocampal neurons; however, in humans, only for the hippocampus has evidence been found for significant levels of neurogenesis in the adult CNS."
        },
        {
            "id": "Pharmacology_Katzung_7259",
            "title": "Pharmacology_Katzung",
            "content": "The mechanisms by which drug interactions alter drug distribution include (1) competition for plasma protein binding, displacement from tissue binding sites, and (3) alterations in local tissue barriers, eg, P-glycoprotein inhibition in the blood-brain barrier. Although competition for plasma protein binding can increase the free concentration (and thus the effect) of the displaced drug in plasma, the increase will be transient owing to a compensatory increase in drug disposition. The clinical importance of protein binding displacement has been overemphasized; current evidence suggests that such interactions are unlikely to result in adverse effects. Displacement from tissue binding sites would tend to transiently increase the blood concentration of the displaced drug. (Text continues on page 1171.) TABLE 66\u20131 Important drug interactions."
        },
        {
            "id": "InternalMed_Harrison_7602",
            "title": "InternalMed_Harrison",
            "content": "with glioblastoma include targeted molecular agents directed at receptor tyrosine kinases and signal transduction pathways; antiangiogenic agents, especially those directed at the VEGF receptors; chemotherapeutic agents that cross the blood-brain barrier more effectively than currently available drugs; gene therapy; immunotherapy; and infusion of radiolabeled drugs and targeted toxins into the tumor and surrounding brain by means of convection-enhanced delivery."
        },
        {
            "id": "Neurology_Adams_5035",
            "title": "Neurology_Adams",
            "content": "Microvascular transudative factors, such as proteases released by tumor cells, also contribute to vasogenic edema by loosening the blood\u2013brain barrier and allowing passage of blood proteins. The small protein fragments that are generated by this protease activity may exert osmotic effects as they spread through the white matter of the brain. This is the postulated basis of the regional swelling, or localized cerebral edema that surrounds the tumor. Experimentally, the increase in permeability has been shown to vary inversely with the molecular weight of various markers; for example, inulin (molecular weight: 5,000) enters the intercellular space more readily than albumin (molecular weight: 70,000)."
        },
        {
            "id": "Pharmacology_Katzung_52",
            "title": "Pharmacology_Katzung",
            "content": "In only a few situations is it possible to apply a drug directly to its target tissue, eg, by topical application of an anti-inflammatory agent to inflamed skin or mucous membrane. Most often, a drug is administered into one body compartment, eg, the gut, and must move to its site of action in another compartment, eg, the brain in the case of an antiseizure medication. This requires that the drug be absorbed into the blood from its site of administration and distributed to its site of action, permeating through the various barriers that separate these compartments. For a drug given orally to produce an effect in the central nervous system, these barriers include the tissues that make up the wall of the intestine, the walls of the capillaries that per-fuse the gut, and the blood-brain barrier, the walls of the capillaries that perfuse the brain. Finally, after bringing about its effect, a drug should be eliminated at a reasonable rate by metabolic inactivation, by excretion from the"
        },
        {
            "id": "Neurology_Adams_4811",
            "title": "Neurology_Adams",
            "content": "Studies using radioisotopic tracer techniques confirm that the main constituents of the CSF (see Table 2-2) are in dynamic equilibrium with the blood. Similarly, CSF in the ventricles and subarachnoid spaces is in equilibrium with the intercellular fluid of the brain, spinal cord, and olfactory and optic nerves. Certain structures and physiologic mechanisms that maintain this equilibrium are subsumed under the term blood\u2013brain barrier, which is used to designate all of the interfaces between blood, brain, spinal cord and CSF. The site of the barrier varies for the different plasma constituents. One is the endothelium of the choroidal and brain capillaries; another is the plasma membrane and adventitia (Rouget cells) of these vessels; a third is the pericapillary foot processes of astrocytes. Large molecules, such as albumin, are prevented from entry by the capillary endothelium, and this is the barrier also for such molecules as are bound to album in, for example, aniline dyes (trypan"
        },
        {
            "id": "InternalMed_Harrison_379",
            "title": "InternalMed_Harrison",
            "content": "FIgURE 5-5 A. The efflux pump P-glycoprotein excludes drugs from the endothelium of capillaries in the brain and so constitutes a key element of the blood-brain barrier. Thus, reduced P-glycoprotein function (e.g., due to drug interactions or genetically determined variability in gene transcription) increases penetration of substrate drugs into the brain, even when plasma LIVER dISEASE concentrations are unchanged. B. The graph shows an effect of a \u03b21-receptor polymorphism on Standard tests of liver function are not use-receptor function in vitro. Patients with the hypofunctional variant (red) may display lesser heart-ful in adjusting doses in diseases like heparate slowing or blood pressure lowering on exposure to a receptor blocking agent. titis or cirrhosis. First-pass metabolism may"
        },
        {
            "id": "Pharmacology_Katzung_6355",
            "title": "Pharmacology_Katzung",
            "content": "in human lung cells. Titanium dioxide nanoparticles that are widely used in sunscreens, other cosmetics, pharmaceuticals, and many other products have been noted to be toxic in the lungs and elsewhere."
        },
        {
            "id": "Pharmacology_Katzung_54",
            "title": "Pharmacology_Katzung",
            "content": "A. Permeation Drug permeation proceeds by several mechanisms. Passive diffusion in an aqueous or lipid medium is common, but active processes play a role in the movement of many drugs, especially those whose molecules are too large to diffuse readily (Figure 1\u20134). Drug vehicles can be very important in facilitating transport and permeation, eg, by encapsulating the active agent in liposomes and in regulating release, as in slow release preparations. Newer methods of facilitating transport of drugs by coupling them to nanoparticles are under investigation. 1. Aqueous diffusion\u2014Aqueous diffusion occurs within the larger aqueous compartments of the body (interstitial space, cytosol, etc) and across epithelial membrane tight junctions and the endothelial lining of blood vessels through aqueous pores that\u2014in some tissues\u2014permit the passage of molecules as large as MW 20,000\u201330,000. * See Figure 1\u20134A."
        },
        {
            "id": "Pharmacology_Katzung_55",
            "title": "Pharmacology_Katzung",
            "content": "* The capillaries of the brain, the testes, and some other tissues arecharacterized by the absence of pores that permit aqueous diffusion.They may also contain high concentrations of drug export pumps (MDR pumps; see text). These tissues are therefore protected or\u201csanctuary\u201d sites from many circulating drugs. FIGURE 1\u20134 Mechanisms of drug permeation. Drugs may diffuse passively through aqueous channels in the intercellular junctions (eg, tight junctions, A), or through lipid cell membranes (B). Drugs with the appropriate characteristics may be transported by carriers into or out of cells (C). Very impermeant drugs may also bind to cell surface receptors (dark binding sites), be engulfed by the cell membrane (endocytosis), and then be released inside the cell or expelled via the membrane-limited vesicles out of the cell into the extracellular space (exocytosis, D)."
        },
        {
            "id": "Neurology_Adams_4812",
            "title": "Neurology_Adams",
            "content": "Large molecules, such as albumin, are prevented from entry by the capillary endothelium, and this is the barrier also for such molecules as are bound to album in, for example, aniline dyes (trypan blue), bilirubin, and many drugs. Other smaller molecules are blocked from entering the brain by active mechanisms at the capillary plasma membrane or astrocytes."
        },
        {
            "id": "Pharmacology_Katzung_58",
            "title": "Pharmacology_Katzung",
            "content": "3. Special carriers\u2014Special carrier molecules exist for many substances that are important for cell function and too large or too insoluble in lipid to diffuse passively through membranes, eg, peptides, amino acids, and glucose. These carriers bring about movement by active transport or facilitated diffusion and, unlike passive diffusion, are selective, saturable, and inhibitable. Because many drugs are or resemble such naturally occurring peptides, amino acids, or sugars, they can use these carriers to cross membranes. See Figure 1\u20134C."
        },
        {
            "id": "Pharmacology_Katzung_1809",
            "title": "Pharmacology_Katzung",
            "content": "catecholamines from the adrenal medulla and stimulate sympathetic ganglia. Bradykinin also increases blood pressure when injected into the central nervous system, but the physiologic significance of this effect is not clear, since it is unlikely that kinins cross the blood-brain barrier. (Note, however, that bradykinin can increase the permeability of the blood-brain barrier to some other substances.) Kinins have no consistent effect on sympathetic or parasympathetic nerve endings."
        },
        {
            "id": "Pharmacology_Katzung_2987",
            "title": "Pharmacology_Katzung",
            "content": "only about 1\u20133% of administered levodopa actually enters the brain unaltered; the remainder is metabolized extracerebrally, predominantly by decarboxylation to dopamine, which does not penetrate the blood-brain barrier. Accordingly, levodopa must be given in large amounts when used alone. However, when given in combination with a dopa decarboxylase inhibitor that does not penetrate the blood-brain barrier, the peripheral metabolism of levodopa is reduced, plasma levels of levodopa are higher, plasma half-life is longer, and more dopa is available for entry into the brain (Figure 28\u20134). Indeed, concomitant administration of a peripheral dopa decarboxylase inhibitor such as carbidopa may reduce the daily requirements of levodopa by approximately 75%."
        },
        {
            "id": "Pharmacology_Katzung_1657",
            "title": "Pharmacology_Katzung",
            "content": "the first-generation drugs and are substrates of the P-glycoprotein transporter in the blood-brain barrier; as a result, they enter the central nervous system with difficulty or not at all. Many H1 antagonists have active metabolites. The active metabolites of hydroxyzine, terfenadine, and loratadine are available as drugs (cetirizine, fexofenadine, and desloratadine, respectively)."
        },
        {
            "id": "Pharmacology_Katzung_6352",
            "title": "Pharmacology_Katzung",
            "content": "Nanomaterials are defined as any material, natural or manufac tured, that has at least one dimension that lies between 1 and 100 nanometers (nm) in size. The Stanford University Health and Safety Department gives a more precise definition at https://ehs. stanford.edu/topic/hazardous-materials/nanomaterials. Nanomaterials have been of increasing commercial interest and are now used for an extraordinary range of purposes. In the phar maceutical manufacturing industry, nanoparticles are being tested and used to deliver cancer chemotherapeutic and other drugs."
        },
        {
            "id": "InternalMed_Harrison_30638",
            "title": "InternalMed_Harrison",
            "content": "There is no known effective therapy for preventing or treating CJD. The finding that phenothiazines and acridines inhibit PrPSc formation in cultured cells led to clinical studies of quinacrine in CJD patients. Unfortunately, quinacrine failed to slow the rate of cognitive decline in CJD, possibly because therapeutic concentrations in the brain were not achieved. Although inhibition of the P-glycoprotein (Pgp) transport system resulted in substantially increased quinacrine levels in the brains of mice, the prion incubation times were not extended by treatment with the drug. Whether such an approach can be used to treat CJD remains to be established."
        },
        {
            "id": "Pathology_Robbins_1850",
            "title": "Pathology_Robbins",
            "content": "blood. Ingested lead is particularly harmful to children because they absorb more than 50% of lead from food, whereas adults absorb approximately 15%. A more permeable blood\u2013brain barrier in children creates a high susceptibility to brain damage. The clinical features of lead poisoning are shown in"
        },
        {
            "id": "Pharmacology_Katzung_53",
            "title": "Pharmacology_Katzung",
            "content": "the walls of the capillaries that perfuse the brain. Finally, after bringing about its effect, a drug should be eliminated at a reasonable rate by metabolic inactivation, by excretion from the body, or by a combination of these processes."
        },
        {
            "id": "Pharmacology_Katzung_2982",
            "title": "Pharmacology_Katzung",
            "content": "Dopamine does not cross the blood-brain barrier and if given into the peripheral circulation has no therapeutic effect in parkinsonism. However, (\u2013)-3-(3,4-dihydroxyphenyl)-l-alanine (levodopa), the immediate metabolic precursor of dopamine, does enter the brain (via an l-amino acid transporter, LAT), where it is decarboxylated to dopamine (see Figure 6\u20135). Several noncatecholamine dopamine receptor agonists have also been developed and may lead to clinical benefit, as discussed in the text that follows."
        },
        {
            "id": "InternalMed_Harrison_11077",
            "title": "InternalMed_Harrison",
            "content": "No effective therapy for PML is available. There are case reports of potential beneficial effects of the 5-HT2a receptor antagonist mirtazapine, which may inhibit binding of JCV to its receptor on oligodendrocytes. Retrospective noncontrolled studies have also suggested a possible beneficial effect of treatment with interferon-\u03b1. Neither of these agents has been tested in randomized controlled clinical trials. A prospective multicenter clinical trial to evaluate the efficacy of the antimalarial drug mefloquine failed to show benefit. Intravenous and/or intrathecal cytarabine were not shown to be of benefit in a randomized controlled trial in HIV-associated PML, although some experts suggest that cytarabine may have therapeutic efficacy in situations where breakdown of the blood-brain barrier allows sufficient CSF penetration. A randomized controlled trial of cidofovir in HIV-associated PML also failed to show significant benefit. Because PML almost invariably occurs in"
        },
        {
            "id": "Physiology_Levy_2070",
            "title": "Physiology_Levy",
            "content": "Changes in cerebral blood flow are associated with \u201cfunctional recruitment\u201d of capillaries. Thus the rate of flow through each capillary is adjusted to meet the needs of the organ. In \u201ccapillary recruitment,\u201d in contrast, more capillaries are open to accommodate greater blood flow. The brain has several protective mechanisms that regulate blood flow. These mechanisms include the blood-brain barrier, extrinsic regulation of central cardiovascular centers, intrinsic control (autoregulation) of circulation, and functional hyperemia, in which blood flow increases to a brain region that is active. The blood-brain barrier regulates ion and nutrient transport between the blood and the brain and also limits the entry of harmful substances from the blood into the brain. The \u2022Fig. 17.40 Diagram of a Neurovascular Unit With an Astrocyte Linking a Neuron to an Arteriole of the Brain Microcirculation."
        }
    ],
    "scores": [
        0.03770964606300567,
        0.037466870820230425,
        0.03623097139038208,
        0.03427046025966686,
        0.033839136885767666,
        0.028846186788527094,
        0.027624292232337255,
        0.02635207929325576,
        0.02541268180488614,
        0.024581719334012913,
        0.02445619609510384,
        0.023895876222336594,
        0.02362866337618195,
        0.023013772118056774,
        0.02235092235092235,
        0.021409700735726327,
        0.021371266332927248,
        0.019945600842778265,
        0.01960972796308757,
        0.018624393624393623,
        0.01837336704593342,
        0.016950369891546364,
        0.016611524676040806,
        0.01630151278038602,
        0.016224038134150496,
        0.016061980347694634,
        0.015934065934065933,
        0.015830309097734953,
        0.01578785075547333,
        0.015648878293294213,
        0.0155842683894367,
        0.015141242937853107
    ]
}